Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Breast cancer brain metastasis remains a significant clinical problem. Mucins have been implicated in metastasis; however, whether they are also involved in breast cancer brain metastasis remains unknown. We queried databases of patients with brain metastasis and found mucin 5AC (MUC5AC) to be upregulated and therefore sought to define the role of MUC5AC in breast cancer brain metastasis.
Experimental Design: In silico dataset analysis, RNA-sequence profiling of patient samples and cell lines, analysis of patient serum samples, and in vitro/in vivo knockdown experiments were performed to determine the function of MUC5AC in breast cancer brain metastasis. Coimmunoprecipitation was used to unravel the interactions that can be therapeutically targeted.
Results: Global in silico transcriptomic analysis showed that MUC5AC is significantly higher in patients with breast cancer brain metastasis. Analysis of archived breast cancer brain metastasis tissue further revealed significantly higher expression of MUC5AC in all breast cancer subtypes, and high MUC5AC expression predicted poor survival in HER2+ breast cancer brain metastasis. We validated these observations in breast cancer brain metastatic cell lines and tissue samples. Interestingly, elevated levels of MUC5AC were detected in the sera of patients with breast cancer brain metastasis. MUC5AC silencing in breast cancer brain metastatic cells reduced their migration and adhesion in vitro and in brain metastasis in the intracardiac injection mouse model. We found high expression of cMET and CD44v6 in breast cancer brain metastasis, which increased MUC5AC expression via hepatocyte growth factor signaling. In addition, MUC5AC interacts with cMET and CD44v6, suggesting that MUC5AC promotes breast cancer brain metastasis via the cMET/CD44v6 axis. Inhibition of the MUC5AC/cMET/CD44v6 axis with the blood-brain barrier-permeable cMET inhibitor bozitinib (PLB1001) effectively inhibits breast cancer brain metastasis.
Conclusions: Our study establishes that the MUC5AC/cMET/CD44v6 axis is critical for breast cancer brain metastasis, and blocking this axis will be a novel therapeutic approach for breast cancer brain metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882111 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-24-1977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polygenic scores in Familial breast cancer cases with and without pathogenic variants and the risk of contralateral breast cancer.
Breast Cancer Res
September 2025
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Background: Polygenic risk scores (PRS) are not yet standard in clinical risk assessments for familial breast cancer in Sweden. This study evaluated the distribution and impact of an established PRS (PRS) in women undergoing clinical sequencing for hereditary breast cancer.
Findings: We integrated PRS into a hereditary breast cancer gene panel used in clinical practice and calculated scores for 262 women.
Investigation of survivin and autophagy marker expression in different Indian cancer tissue samples.
J Mol Histol
September 2025
Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, 605014, India.
Survivin, an inhibitor of apoptosis protein, is minimally expressed in normal adult tissues but overexpressed in multiple cancers. This study investigates survivin expression alongside autophagy markers ATG7 and LC3B in seven solid tumor types in Indian patient samples. Immunohistochemical analysis was performed on 48 cancer tissue samples (breast n = 7, buccal n = 6, cervical n = 5, colon n = 8, renal n = 6, liver n = 10, thyroid n = 6) and adjacent normal tissues (n = 9) using anti-human antibodies against survivin, ATG7, and LC3B.
View Article and Find Full Text PDFCognitive-behavioral and mindfulness-based therapies for mental health and quality of life of breast cancer patients: a meta-analysis of randomized controlled trials.
Int J Clin Oncol
September 2025
Institute for Applied Research in Public Health, School of Public Health, Nantong University, Nantong, China.
Background: To evaluate the effects of cognitive-behavioral therapy (CBT) and mindfulness-based therapy (MBT), individually and in combination, on alleviating anxiety and depression, and improving quality of life (QoL) in breast cancer patients.
Methods: We searched PubMed and EMBASE for articles published up to April 6, 2025, using the keywords "randomized controlled trials (RCTs)", "cognitive-behavioral therapy", "mindfulness-based therapy", and "breast cancer". Pooled effects were expressed as standardized mean differences (SMDs) and 95% confidence intervals (CIs).
Synaptotagmin-like 5 is a potential biomarker and correlates with immune infiltrates in thyroid carcinoma.
J Mol Histol
September 2025
Department of Endocrinology, The Third Affiliated Hospital of Soochow University, No.185 Juqian Road, Changzhou, 213003, China.
Thyroid carcinoma (TC) continues to show concerning rates of metastasis and recurrence, despite an overall favorable prognosis. This study aimed to investigate the characteristics and predictive value of synaptotagmin-like 5 (SYTL5) expression and its association with immune infiltration and potential effects on cell apoptosis and proliferation in TC. Messenger ribonucleic acid expression profiles from 45 TC samples and 37 normal samples in The Cancer Genome Atlas database were analysed.
View Article and Find Full Text PDFAuthor Correction: Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation.
Sci Rep
September 2025
Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Science, 279Th Zhouzhu Road, Shanghai, 201318, China.